FDA Lotronex Letter Cites Desire To Work With Glaxo To Maintain Therapy
Executive Summary
FDA is willing to continue working with Glaxo Wellcome on a risk management program for Lotronex, the agency said in a Dec. 18 letter to consumers.
You may also be interested in...
GSK Lotronex Limited-Access Program Revisited By FDA In Patient Letter
FDA is revisiting the dispute over a limited-access program for GlaxoSmithKline's withdrawn irritable bowel syndrome drugLotronex
GSK Lotronex Limited-Access Program Revisited By FDA In Patient Letter
FDA is revisiting the dispute over a limited-access program for GlaxoSmithKline's withdrawn irritable bowel syndrome drugLotronex
Lotronex Risk Factor Identification Is Prerequisite To Return, FDA Says
GlaxoSmithKline and FDA are discussing ways to identify risk factors for Lotronex adverse events as a foundation for a risk management plan for the irritable bowel syndrome therapy.